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  EVIDENCE-BASED ANSWER 
In adults with no history of cardiovascular disease, aspirin reduces the risk of nonfatal myocardial infarction 
(MI). Aspirin prophylaxis does not decrease all-cause mortality, risk of fatal coronary heart disease, or risk of 
first stroke (strength of recommendation [SOR]: A–, based on multiple randomized controlled trials). 
The benefits of aspirin use must be weighed against its potential risks, primarily gastrointestinal bleeding and 
cerebral hemorrhage. The benefit of aspirin increases with higher levels of cardiovascular risk, while the 
potential for harm remains relatively constant. Adults with a calculated 5-year coronary heart disease (CHD) 
event risk of 3% or greater should receive prophylaxis (SOR: A, based on multiple randomized controlled 
trials). The ideal dose of aspirin for prophylaxis is unknown, but it appears that low doses (75–81 mg/d) are as 
effective as higher doses. 
  EVIDENCE SUMMARY 
The leading cause of morbidity and mortality in the United States is cardiovascular disease (ischemic CHD, 
stroke, peripheral vascular disease).1 A meta-analysis of 5 placebo-controlled randomized controlled trials 
involving more than 50,000 patients free of CHD and stroke evaluated aspirin for primary prevention of 
cardiovascular disease. Since 3 of the trials excluded women, only 20% of the participants were female. The 
mean age of participants was 57 years. 
The treatment groups took aspirin 75 to 500 mg/d for 3 to 7 years. The meta-analysis found that compared with 
placebo, aspirin significantly reduced total CHD events (odds ratio [OR]=0.72; 95% confidence interval [CI], 
0.60–0.87).2 Aspirin did not reduce coronary disease mortality (OR=0.87; 95% CI, 0.70–1.09); however, results 
from 1 study did achieve statistical significance (OR=0.64; 95% CI, 0.42–0.99).3 No differences were found 
between aspirin-treated and control groups for all-cause mortality or ischemic stroke reduction. 
Aspirin increased the risk of major gastrointestinal bleeding events by almost twofold (OR=1.70; 95% CI, 1.4–
2.1). Three of the 5 trials showed no significant increase of intracranial hemorrhage event rates (OR=1.4; 95% 
CI, 0.9–2.0). Based on combined primary and secondary prevention trials, the risk of intracranial bleeding with 
aspirin is estimated at 0 to 2 events per 1000 patients per year.2 
Although the ideal aspirin dosage is uncertain, lower dosages (75–81 mg/d) have been shown to be as 
beneficial as higher dosages, and may have fewer bleeding complications. Buffered and entericcoated 
formulations are no more protective than plain aspirin.4 
In patients with no known cardiovascular disease, aspirin chemoprevention has been shown to decrease the 
risk of nonfatal MI and fatal CHD by 28%. At a 5-year CHD risk of 3%, the benefits of prophylaxis outweigh the 
harms (see Table ) by 2 to 1—assuming the events of stroke, MI, and bleeding are considered roughly 
equivalent in severity. (A different threshold may be appropriate for patients that perceive 1 of these events as 
significantly more serious than the others.) Typical patients at a 3% or greater risk for cardiovascular disease 
include men aged >40 years, post-menopausal women, and younger persons with risk factors for CHD. 
Physicians determine cardiovascular risk from the presence and severity of risk factors: gender, age, blood 
pressure, lipid status, diabetes, and smoking status. 
Simple risk-assessment tools based on Framingham data are available for computers and palmtop devices 
(eg, Heart to Heart CV Risk Assessment Calculator, www.meddecisions.com; National Institutes of Health, 
www.nhlbi.nih.gov/health/prof/heart/). Because only 2 trials included women, it is less clear whether both 
sexes benefit equally from aspirin prophylaxis.1 
 
TABLE 
Net benefits and harms of aspirin prophylaxis, per 1000 patients 
Outcome Estimated 5-year risk for CHD event 
   1% 3% 5% 
All-cause mortality NS NS NS 
CHD events avoided 3 8 14 
Ischemic strokes avoided NS NS NS 
Hemorrhagic strokes 1 1 1 
Major gastrointestinal bleeding 3 3 3 
NS, not significant 
  RECOMMENDATIONS FROM OTHERS 
The US Preventive Services Task Force recommends that clinicians discuss aspirin prophylaxis with adults at 
increased risk for CHD (defined as a 5-year risk of 3% or more). Discussion should include the potential 
benefits and harms of aspirin therapy.5 
The American Heart Association recommends low-dose aspirin in people at higher risk of coronary heart 
disease (especially those with a 10-year CHD risk of 10% or greater).6 The European Society of Cardiology 
says there is evidence that low-dose aspirin can reduce the risk of cardiovascular events in asymptomatic high-
risk people, such as those with diabetes or well-controlled hypertension, and in men at high multifactorial risk of 
cardiovascular disease.7 
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Acetylsalicylic acid was first compounded in Germany by chemist Felix Hoffman in 1897. 
According to information from the Bayer Company, aspirin’s cardioprotective effect was 
first recognized by Dr Lawrence Craven, a California general practitioner. He noted a 
decreased rate of heart attacks in patients taking this medication. 
We now have evidence supporting Dr Craven’s astute clinical observation. In adults with 
no history of cardiovascular disease, aspirin reduces the risk of nonfatal MI. For an 
individual at a 5-year CHD risk as low as 3%, the benefits of prophylaxis outweigh the 
harms. The leading cause of morbidity and mortality in the US is still cardiovascular 
disease. A simple, effective, safe, and inexpensive preventive measure like 
recommending aspirin has the potential to prevent heart attacks on a grand scale. A low-
dose aspirin per day should be recommended for patients at risk for cardiovascular 
disease, including men aged >40 years, postmenopausal women, and younger persons 
with risk factors for CHD. As a 40-something male with a family history of cardiovascular 
disease reviewing this Clinical Inquiry, I will be taking my aspirin a day. 
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